Please login to the form below
OSE Immunotherapeutics
This page shows the latest OSE Immunotherapeutics news and features for those working in and with pharma, biotech and healthcare.
Boehringer taps Korea’s Bridge for Ofev follow-up
Last year, Boehringer also acquired the oncolytic virus specialist ViraTherapeutics for 210m and licensed a checkpoint inhibitor from OSE Immunotherapeutics in a deal valued at up to 1bn.
Latest news
-
China’s Innovent to start US trials of anti-CD47 cancer drug
And earlier this year Boehringer Ingelheim licensed a drug from French biotech OSE Immunotherapeutics that targets SIRP-alpha – which binds to CD47 – in a 1.1bn deal.
-
Boehringer bolts on another immuno-oncology company
ViraTherapeutics is just one a of a series of investments Boehringer has made in immuno-oncology, coming after a 1.1bn deal to license a checkpoint inhibitor from French biotech OSE ... Immunotherapeutics and earlier alliances with Siamab, AbeXXa
-
Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal
Boehringer Ingelheim has licensed a new checkpoint inhibitor from French biotech OSE Immunotherapeutics in a deal that could be worth more than 1.1bn (around $1.4bn). ... The deal focuses around OSE-172, an anti-SIRP-alpha antibody with potential in
More from news
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Iris Pauporté joins OSE Immunotherapeutics
She becomes clinical project director at the French biotech. Nantes, France-based biotech OSE Immunotherapeutics has bolstered its clinical team with the appointment of Iris Pauporté as clinical project director. ... Alain Chatelin, medical director at
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
- Want the most from your Pharmaceutical portfolio?
- Diversity and inclusion in clinical trials: keeping up momentum
- 10 Important Advisor Questions: Placement of Your Product in the Current/Future Treatment Algorithm
- Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia
No results were found
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
